Genomic Health, Inc. (GHDX) Expected to Announce Quarterly Sales of $106.76 Million

Equities analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to report sales of $106.76 million for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Genomic Health’s earnings, with estimates ranging from $104.87 million to $108.20 million. Genomic Health posted sales of $92.63 million during the same quarter last year, which suggests a positive year over year growth rate of 15.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, May 1st.

On average, analysts expect that Genomic Health will report full year sales of $445.00 million for the current year, with estimates ranging from $438.47 million to $450.85 million. For the next year, analysts expect that the company will post sales of $492.25 million, with estimates ranging from $480.72 million to $503.40 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Genomic Health.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Wednesday, February 20th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.02. The business had revenue of $104.56 million for the quarter, compared to the consensus estimate of $101.55 million. Genomic Health had a return on equity of 16.86% and a net margin of 6.52%. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.05 earnings per share.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Genomic Health from a “buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub downgraded shares of Genomic Health from a “buy” rating to a “hold” rating in a research note on Saturday, March 30th. ValuEngine downgraded shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, March 5th. Piper Jaffray Companies boosted their price target on shares of Genomic Health to $86.00 and gave the stock a “neutral” rating in a research note on Thursday, February 21st. Finally, Needham & Company LLC restated a “strong-buy” rating and issued a $97.00 price target (up previously from $86.00) on shares of Genomic Health in a research note on Thursday, February 21st. Ten investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $63.13.

In related news, Director Bros. Advisors Lp Baker sold 11,204 shares of the business’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $65.32, for a total transaction of $731,845.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO G Bradley Cole sold 15,000 shares of the business’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $67.61, for a total transaction of $1,014,150.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,871,600 shares of company stock valued at $136,156,302. Insiders own 45.80% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc raised its position in shares of Genomic Health by 18.6% during the 3rd quarter. Vanguard Group Inc now owns 2,151,932 shares of the medical research company’s stock worth $151,109,000 after buying an additional 337,664 shares in the last quarter. Vanguard Group Inc. grew its holdings in Genomic Health by 18.6% during the third quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock valued at $151,109,000 after purchasing an additional 337,664 shares during the period. Norges Bank bought a new stake in Genomic Health during the fourth quarter valued at about $20,975,000. Copper Rock Capital Partners LLC bought a new stake in Genomic Health during the fourth quarter valued at about $18,630,000. Finally, FMR LLC grew its holdings in Genomic Health by 83.8% during the fourth quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock valued at $35,466,000 after purchasing an additional 251,085 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.

NASDAQ:GHDX opened at $65.93 on Wednesday. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 62.79 and a beta of 0.95. Genomic Health has a 52 week low of $31.05 and a 52 week high of $92.18.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Read More: What is the NASDAQ?

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.